L&C Bio Co., Ltd. (290650.KQ) shares jumped almost 12% Thursday on plans for an Ozempic face repair made out of donated human fats.
The KOSDAQ-listed inventory reached 64,600 gained intraday, up 11.76%, per Yahoo Finance knowledge, extending a five-day acquire of roughly 24%. Buyers welcomed the information as a recent development avenue past the agency’s present skincare line.
An Ozempic Facet Impact Turns into a Enterprise Plan
GLP-1 (glucagon-like peptide-1) medication reminiscent of Ozempic drive fast weight reduction. Some customers then develop a gaunt, hollowed look often known as “Ozempic face,” and L&C Bio needs to deal with that hole instantly.
The market behind that downside is increasing quick. J.P. Morgan Analysis initiatives the U.S. affected person base for GLP-1 medication will climb from 12.9 million in 2026 to 30.3 million by 2030, break up between sort 2 diabetes and weight problems sufferers. Every new weight problems affected person on an Ozempic-class drug is a possible candidate for facial quantity loss, and subsequently a possible buyer for L&C Bio.
The corporate’s deliberate product, tentatively named MegaAdipoECM, converts donated human fats into an extracellular matrix scaffold. Sufferers’ personal fats cells then repopulate the handled space, restoring quantity with out artificial filler.
“We pioneered using donated human tissue in Okay-beauty pores and skin boosters.”
Lee Whan Chul, CEO, L&C Bio (SCMP)
The method differs from Re2O, L&C Bio’s flagship product, which makes use of donated pores and skin tissue for wrinkles relatively than quantity. In the meantime, the brand new booster might additionally function an alternative choice to silicone breast implants, widening its potential market past Ozempic customers alone.
A Authorized Shift Unlocks a Low-cost Uncooked Materials
South Korean legislation beforehand categorised donated fats as medical waste, which blocked industrial use solely. That modified in 2026, when regulators reclassified the tissue. Nevertheless, a one-year grace interval means L&C Bio doesn’t anticipate a industrial launch earlier than late 2027.
The delay has not dampened investor enthusiasm. L&C Bio holds patents in South Korea, america, and China, the three markets it plans to focus on first. Subsequently, L&C Bio already has authorized safety earlier than any product reaches cabinets. That safety turns a waste product right into a low-cost enter for a world aesthetics enterprise constructed round Ozempic-era demand.
The rally additionally lands inside a rocky 2026 for Korean equities. Buying and selling volumes cratered throughout a KOSDAQ crash this 12 months, and a chip inventory selloff additionally rattled the KOSPI in July. Some merchants even confirmed indicators of capital fleeing to crypto throughout previous fairness swoons.
L&C Bio’s bounce suggests a robust biotech story can nonetheless lower by that volatility. The inventory now carries a market capitalization of 1.578 trillion gained, on quantity of 366,542 shares, near its common.
Yahoo Finance knowledge additionally lists a one-year worth goal of 99,000 gained, nicely above Thursday’s degree. Nevertheless, the inventory’s 52-week vary of 29,100 to 125,000 gained reveals simply how unstable shares have already been.
Whether or not L&C Bio turns patent safety into income by 2027 stays the open query for this Ozempic face repair.
The publish L&C Bio’s Human-Fats Injection May Repair “Ozempic Face”: Will Positive factors Maintain? appeared first on BeInCrypto.